Defining HFpEF: where do we draw the line?

Affiliations

Editorial

Barry A Borlaug. Eur Heart J. 2016.

. 2016 Feb 1;37(5):463-5.

doi: 10.1093/eurheartj/ehv561. Epub 2015 Nov 3.

¹ The Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic Rochester, MN, USA borlaug.barry@mayo.edu.

No abstract available

Comment on

Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, O'Meara E, Shah SJ, McKinlay S, Fleg JL, Sopko G, Pitt B, Pfeffer MA; TOPCAT Investigators. Solomon SD, et al. Eur Heart J. 2016 Feb 1;37(5):455-62. doi: 10.1093/eurheartj/ehv464. Epub 2015 Sep 15. Eur Heart J. 2016. PMID: 26374849 Free PMC article. Clinical Trial.